Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase…
Anebulo Pharmaceuticals Announces New CEO Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (“ACI”), today announced that Richie Cunningham has been appointed as Anebulo’s Chief Executive Officer, replacing Simon…
RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures RevBio, Inc., announced that it has been awarded a grant from the National Institute on Aging (NIA), part of the National Institutes of…
Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced its participation in the Immunoglobulin National Society (IgNS) 12th National Conference, which takes place on October 5th – 8th in Denver, Colorado. The annual conference provides a forum for industry leaders across…
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston…
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to…
Hey Jane Launches Comprehensive Reproductive and Sexual Health Services in the District of Columbia Hey Jane, the patient-centered, virtual reproductive and sexual health care clinic, announced the expansion of its services to the District of Columbia. This launch not only…
Sphere Fluidics’ Cyto-Mine System Selected by FairJourney Biologics to Advance Cell Line Development Workflows Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the Cyto-Mine® platform has been selected by FairJourney Biologics, a world…
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Kevin E. Lofton, Lead Independent Director,has been named oneof the most influential leaders in corporate governance by the National Association…
ew Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data showing that disrupting the recommended TEPEZZA treatment regimen by…
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer –Faeth Therapeutics, a clinical-stage biotechnology company targeting cancer metabolism, today announced the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer. Dr. Chirnomas will head up the early…
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low, or negative breast cancer in TROPION-Breast01 Phase III trial Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically…
